257 -5 (79) 2025 - Kazakov B.Sh., Jumayeva Z.K. - THROMBOCYTOPENIC PURPURA IN THE ELDERLY. DISCUSSION OF THERAPY

THROMBOCYTOPENIC PURPURA IN THE ELDERLY. DISCUSSION OF THERAPY

Kazakov B.Sh. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Jumayeva Z.K. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Idiopathic thrombocytopenic purpura is a life-threatening chronic autoimmune disease. It is characterized by a periodic or permanent decrease in the number of platelets (less than 100x109/l) in a person’s peripheral blood, low levels of coagulation and an increased risk of bleeding. Idiopathic thrombocytopenic purpura is the most common cause of hemorrhagic syndrome, i.e. excessive bleeding. The incidence of this nosology is quite rare and amounts to 1–13 cases per 100 thousand adult population. This article discusses the foreign literature studied, as well as views on first- and second-line therapy

Keywords: idiopathic thrombocytopenic purpura, DIC syndrome, hemorrhagic syndrome, therapy of idiopathic thrombocytopenic purpura

First page

1281

Last page

1285

For citation:Kazakov B.Sh., Jumayeva Z.K. - THROMBOCYTOPENIC PURPURA IN THE ELDERLY. DISCUSSION OF THERAPY//New Day in Medicine 5(79)2025 1281-1285 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

  1. Захарова Н.Н., Богданова М.А. Тромбоцитопении у взрослых: диагностика и лечение // Гематология. – 2020. – №2. – С. 45–58.
  2. Кондратьева Т.И., Савченко В.Г. Иммунная тромбоцитопеническая пурпура: современные подходы к терапии // Клиническая медицина. – 2021. – №7. – С. 25–31.
  3. Петрова М.С. Особенности течения тромбоцитопенической пурпуры у пациентов старшего возраста // Вопросы гериатрии. – 2018. – №4. – С. 15–21.
  4. Bussel J.B., et al. Long-term outcomes of adults with chronic ITP after splenectomy failure: a systematic review // Hematology. – 2020. – Vol. 25(1). – P. 1–9.
  5. Bussel J.B., Arnold D.M., Grossbard E. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a 2020 perspective // American Journal of Hematology. – 2020. – Vol. 95(7). – P. 834–841.
  6. Neunert C., et al. Severe bleeding events in adults with primary immune thrombocytopenia: a systematic review // Haematologica. – 2015. – Vol. 100(6). – P. 712–718.
  7. McCrae K.R. Immune thrombocytopenia: no longer “idiopathic” // Cleveland Clinic Journal of Medicine. – 2011. – Vol. 78(5). – P. 358–373.
  8. Provan D., et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia // Blood Advances. – 2019. – Vol. 3(22). – P. 3780–3817.
  9. Rodeghiero F., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group // Blood. – 2009. – Vol. 113(11). – P. 2386–2393.
  10. Vorobyev PA, Krasnova LS, Borisenko OV, Shustov AG. [Clinical and economic evaluation of thrombopoietin receptor agonists in the treatment of chronic idiopathic hrombocytopenic purpura in adults]. Modern Pharmacoeconomic and Pharmacoepidemiology. 2012; 4 (1): 10-17.
  11. Zhang X., et al. Management of immune thrombocytopenia in elderly patients: challenges and solutions // Journal of Blood Medicine. – 2019. – Vol. 10. – P. 123–135.

    file

    download